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Abstract
Aim The mTOR-inhibitor rapamycin has shown antitumor activity in various tumors. Bedside observations have suggested
that rapamycin may be effective as a treatment for colorectal carcinomatosis.
Methods We established an orthotopic syngenic model by transplanting CT26 peritoneal tumors in Balb/C mice and an
orthotopic xenograft model by transplanting SW620 peritoneal tumors in nu/nu mice. Expression levels of tissue inhibitor of
matrix-metalloproteinases 1 (TIMP-1) in the tumor and serum was determined by enzyme-linked immunosorbent assay.
Results Rapamycin significantly suppressed growth of syngenic and xenografted peritoneal tumors. The effect was similar
with intraperitoneal or oral rapamycin administration. Tumor suppression was further enhanced when rapamycin was
combined with 5-fluorouracil and/or oxaliplatin. The combination treatment showed no acute toxicity. TIMP-1 serum levels
correlated well (CC=0.75; P<0.01) with rapamycin treatment.
Conclusions Rapamycin suppressed advanced stage colorectal cancer, even with oral administration. Combining rapamycin
with current chemotherapy regimens significantly increased antitumor efficacy without apparent toxicity. The treatment
efficacy correlated with serum TIMP-1 levels, suggesting its potential as a surrogate marker in future clinical trials.
Keywords mTOR inhibitor . Rapamycin . 5-FU .
Oxaliplatin . TIMP-1 . Colorectal cancer
Introduction
About 25% of patients with symptoms from colorectal
cancer show peritoneal seeding of tumor cells (peritoneal
carcinomatosis).1 The prognosis for patients with peritoneal
carcinomatosis is somber. The estimated 5-year survival is
less than 10%,2 despite improved tumor responses to
combinations of basic chemotherapy (5-fluorouracil [5-
FU] + leucovorin) with either Irinotecan or oxaliplatin
(FOLFOX) and more recently with bevacizumab. To
significantly improve survival for these patients, novel
treatment strategies are needed.
Rapamycin is a bacterial macrolide that forms a complex
with the FK506-binding protein (FKBP-12) and inactivates
the mammalian target of rapamycin (mTOR). mTOR is
activated through the phosphoinositide 3 kinase (PI3K),
protein kinase B/rat sarcoma (Akt/Ras) pathway and leads
to protein synthesis and cell proliferation. Accordingly,
aberrant activation of mTOR has been observed in more
than 30% of epithelial cancers (reviewed in3,4). Nearly 40%
of carcinomas of the colorectum exhibit either partial or
complete positive staining for a downstream factor of
mTOR, phospho-S6K. This suggests that they are
rapamycin-sensitive lesions.5 However, the antitumor ac-
tivity of rapamycin is two-pronged; it has direct antiproli-
ferative effects and also inhibits tumor-angiogenesis.6,7
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Seeliger et al. reported that rapamycin increased antitumor
activity by counteracting 5-FU-induced expression of
angiogenetic 2-deoxy-ribose (dRib) in a mouse colorectal
tumor model.8 Other groups have reported various syner-
gistic effects of rapamycin with experimental agents,
including radiation therapy and the DNA-damaging agents,
cisplatin, oxaliplatin, and doxorubicin.9–14
Several synthetic rapamycin homologues have been
tested in clinical trials for brain tumors, renal cell
carcinoma, gynecologic cancer, lung cancer, and sarcomas
(reviewed in Figlin15).16–19 However, early clinical trials
have been hampered by difficulties in demonstrating
biologic activity of the tested compound in advanced
disease.
In order to set the stage for rapamycin therapy in
advanced colorectal cancer, it would be desirable to identify
a suitable surrogate marker to monitor antitumor activity.
The tissue inhibitor of matrix metalloproteinases 1 (TIMP-
1) has been shown to correlate with disease stage and
tumorigenicity of colorectal cancer20,21(and reviewed in22).
TIMP-1 shares homology with its three other family
members, and all display a robust sensitivity to changes in
pH, temperature, and denaturing conditions due to their
disulphide bonds.23 The N-terminal domain displays inhib-
itory activity against matrix metalloproteinases (MMPs)
and contains the consensus sequence VIRAK.24 TIMP-1 is
expressed and secreted by many cells of most tissues. The
TIMP-1 protein includes a signal peptide that directs its
secretion into the extracellular space. One of the main
functions of TIMP-1 is the inhibition of MMPs. This
activity is involved in the tissue remodeling observed in
inflammation, wound healing, and cancer invasion.25,26
TIMP-1 binding to the cell surface activates the PI3K
signaling pathway, which leads to cell proliferation.27,28
Conversely, inhibition of the PI3K pathway through PTEN
(a tumor suppressor that prevents phosphorylation of Akt)
resulted in down-regulation of epidermal growth factor-
induced TIMP-1 expression.29 Because it has also been
reported that rapamycin caused down-regulation of TIMP-1
expression in experimental transplant rejection, we were
interested in whether serum TIMP-1 expression levels
might serve as a surrogate marker for the efficacy of
rapamycin-based anticancer regimens.30,31
Material and Methods
Cell Lines and Chemicals
SW620 human colonic carcinoma cells and CT26 mouse
colon carcinoma cells (derived from a murine Balb/c colon
carcinoma) were obtained from the American Type Culture
Collection (Rockville, MD, USA). We obtained 3-(4,5-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), tetrazolium salt, and all other chemicals and
reagents from Sigma Chemical Corp. (Buchs, Switzerland).
Immunohistochemistry was performed with rabbit anti-
TIMP-1 (H-150; Santa Cruz Biotechnology; LabForce
AG, Nunningen, Switzerland). The substrate solution for
enzyme-linked immunosorbent assay (ELISA; ImmunoPure
TMB Substrate Kit) were from Pierce (Perbio Science,
Lausanne, Switzerland). The DuoSet kit (ELISA Develop-
ment System) was used with mouse (DY980) and human
anti-TIMP-1 (DY970) antibodies from R&D Systems Inc.
(Minneapolis, USA). Rapamycin (Rapamune ®) was from
Wyeth Pharmaceuticals (Zug, Switzerland), 5-FU was from
Roche Pharma (Reinach, Switzerland), and oxaliplatin was
from Sanofi-Synthélabo (Meyrin, Switzerland).
Cell Cytotoxicity Assay
Cell cytotoxicity was determined as described previously32
by colorimetric assays (MTT dye reduction assay) per-
formed with the Ultra-microplate reader EL808 (Bio-Tek
instruments Inc, Winooski, USA). Cells were plated in
triplicate at a density of 1×104 in 96-well plates in 0.2 ml
normal growth medium and incubated at 37°C, with 5%
CO2. All assays were repeated at least three times.
Orthotopic, Syngenic, and Xenograft Animal Models
Four- to 6-week-old female, 20–25 g Balb/c OlaHsd mice
and athymic Nude-Foxn1nu mice (Harlan Netherlands B.V.,
Horst, Netherlands) were housed in individual ventilated
cages under sterile conditions according to the Swiss
guidelines for the care and use of laboratory animals.
Sterile food and water were provided ad libitum. Animal
procedures were approved by the regional authorities
according to Swiss animal-care regulations. To create an
orthotopic model of peritoneal carcinomatosis, CT26 or
SW620 cells were injected at a density of 5×105 cells/50 μl
into the peritoneal cavity of BALB/c (syngenic model) or
nude mice (xenograft model), respectively. Preliminary
analysis of stably transplanted CT26 cells by biolumines-
cence imaging showed that 100% of mice developed
tumors, and the localization of tumors was reminiscent of
peritoneal carcinomatosis in humans. Five days after tumor-
cell inoculation, once peritoneal carcinomatosis was estab-
lished, treatment was initiated. Mice were followed daily
and killed by CO2 euthanasia when ascites or tumor
development interfered with the well-being of the animals
or at the end of experiments. Tumors from the peritoneal
cavity were carefully excised under a surgical microscope
(magnification ×4). The total excised tumor was weighed,
and the ascites volume was measured. Specimens from the
tumor, colon, liver, and lungs were embedded in paraffin.
1782 J Gastrointest Surg (2009) 13:1781–1790
Antitumor Agents
Rapamycin was diluted in water and administered orally or
intraperitoneally (i.p.) at 0.15 or 1.5 mg/kg every 2 days,
respectively. In mice, a dosage of 1.5 mg kg−1 day−1 has
been shown to produce steady-state rapamycin serum levels
in a range similar to that used on a long-term basis in organ
transplantation to prevent allograft rejection.6 5-FU was
diluted in 0.9% saline and administered i.p. at 100 mg/kg
on days 7 and 14. Thereafter, 5-FU was given at 50 mg/kg
every 7 days to the end of the experiment, as described
previously.6 It was reported that 100 mg/kg 5-FU was the
maximum tolerated dose in mice.33 Oxaliplatin (Eloxatin ®)
was prepared according to the description of the manufac-
turer and administered i.p. at 5 mg/kg/d for 5 days. For
combination treatment experiments with rapamycin + 5-
FU/Oxal, half of the above dose of Oxaliplatin was used.
Cyclosporine A was given orally by gavage at a dose of
15 mg/kg every 2 days as described previously.
Determination of TIMP-1
Cell lysates, tissue lysates, and tail vein serum samples
spun at 1,500×g were analyzed with enzyme-linked
immunosorbent assay for TIMP-1 quantitation according
to manufacturer specifications (DuoSet, ELISA Develop-
ment System, mouse TIMP-1 or human TIMP-1; R&D
Systems Inc., USA). Wells were incubated for 20 min in
substrate solution (ImmunoPure TMB Substrate Kit, Pierce,
USA). The optical density of each well was determined
immediately with a microplate reader (EL808, Microplate
Reader, Bio-Tek Instruments Inc., USA) at a wavelength
of 450 nm (wavelength correction set to 562 nm). A
standard curve was created by reducing the data to a four-
parameter logistic (4-PL) curve fit with KC4-Software
(Kineticalc for Windows; version # 3.03, Rev. # 4, Bio-Tek
Instruments Inc., USA). Comparison of the optical density of
each well to the standard curve provided a relative measure-
ment of protein concentration. Measurements were per-
formed in triplicate.
Immunohistochemistry
Tumor tissue samples were fixed in 4% formalin, pro-
cessed, and embedded in paraffin. Paraffin embedded tissue
samples were sliced into 5 μm sections and processed
according to the manufacturer’s protocol (Vectastain ABC
Elite Kit, Vector Laboratories, Burlingame, CA, USA). For
antigen retrieval, samples were digested with Proteinase K
at a concentration of 5 μg/ml at 37°C for 20 min. Rabbit
polyclonal TIMP-1 antibodies (H-150) were added at a
final concentration of 1 μg/ml, and sections were incubated
overnight at 4°C. Sections were developed with 3,3′-
diaminobenzidine (SigmaFast 3,3′-diaminobenzidine tablet
sets, Sigma-Aldrich, USA) substrate for a maximum of
10 min.
Statistics
Statistical software NCSS (Kaysville, UT, USA) was used
to analyze the data. One-way analysis of variance
(ANOVA) and t tests were used where appropriate. The
significance level was set at 0.05. Whiskers (10th and
90th), box margins (25th and 75th), and the midline of box
plots (50th) depict the percentiles of the respective variable.
Linear regression modeling was used for the estimation of
correlations. The regression coefficient and R2 were
calculated. The Spearman rank correlation coefficient was
used to estimate confidence levels and probabilities.
Results
Rapamycin Inhibited Growth of Peritoneal Carcinomatosis
A dose escalation of rapamycin on CT26/SW620 cells in
vitro showed direct cytotoxicity (determined by MTT
assays) only at very high concentrations (>100 ng/ml; data
not shown). In vivo, rapamycin administered orally
(gavage) or intraperitoneally (i.p.) caused significant sup-
pression of peritoneal tumor growth in Balb/c mice
(syngenic model with CT26 cells; Fig. 1a, b). The
antitumor efficacy of rapamycin at “pharmacological
doses”6 (hd Rap) and at one tenth of that concentration
(ld Rap) was similar to the tumor suppressive activity of 5-
FU or oxaliplatin (Fig. 1a). In contrast, treatment with the
immunosuppressive agent cyclosporine A, another immu-
nosuppressive drug used to inhibit transplant rejection, did
not decrease tumor growth (Fig. 1b). Mice in the
rapamycin-treated group showed very low amounts of
ascites, but mice in the cyclosporine A and control groups
showed marked formation of malignant ascites (Fig. 1c).
Combination of Rapamycin with 5-FU- and/or Oxaliplatin-
Enhanced Growth Inhibition of Syngenic Tumors
with no Apparent Toxicity
Rapamycin combined with either 5-FU or oxaliplatin
showed superior tumor suppression compared to rapamycin
as a single agent therapy (Fig. 2a, b). No acute or chronic
toxicity was noted, but two mice of the oxaliplatin alone
group showed subcutaneous necrosis at the site of injection,
likely due to an inaccurate injection. Body weight was
maintained in balance over most of the observation period.
However, in control treated animals, weight increased in
proportion to apparent ascites and tumor load. This finally
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led to early killing of the animals because interference with
well-being was noted (Fig. 2c). H&E staining of paraffin-
embedded liver samples did not reveal ultrastructural
changes that indicated acute or chronic hepatic toxicity
(analysis by an independent pathologist; Fig. 2d).
Rapamycin Treatment Alone and in Combination Inhibited
Tumor Growth of Human Xenograft Peritoneal
Carcinomatosis
Both rapamycin and “FOLFOX” (5-FU+oxaliplatin) treat-
ments caused significant suppression of the peritoneal tumor
growth induced by human colorectal SW620 cancer in nude
mice. The antitumor effect was enhanced by a combination
of rapamycin with 5-FU+oxaliplatin (Fig. 3). At low doses
of rapamycin (one tenth of the “standard” dose), tumor
suppression was enhanced compared to 5-FU+oxaliplatin
treatment alone. The effect was further enhanced when
rapamycin was given at a high dose. Again, no acute or
chronic toxicity was observed as confirmed by histological
analysis of liver tissue and body weight curves.
TIMP-1 Was Down-Regulated by Rapamycin Treatment
in Cancer Cells and Tumors
CT26 or SW620 cell lysates showed a dose-dependent
decrease in TIMP-1 protein levels after addition of
rapamycin to the culture media (Fig. 4a; CT26). Hence,
low to medium-high doses of rapamycin down-regulated
TIMP-1 expression without apparent toxic effects, as
shown by immunohistochemistry (Fig 4b) and western
blots (not shown). Compared to phosphate-buffered saline
(PBS)-treated mice, the combination of 5-FU and oxalipla-
tin also lowered intratumoral TIMP-1 expression but
significantly less than rapamycin treatment.
Serum Levels of TIMP-1 Correlated with Antitumor
Activity of Rapamycin
The expression levels of TIMP-1 in serum samples from
mice with syngenic CT26 tumors correlated well with
tumor weight (CC=0.76; Fig. 4c). The correlation was
treatment groups
Oxal5FUhd Rapld RapPBS
tu
m
or
 w
ei
gh
t (g
)
3.6
3.2
2.8
2.4
2.0
1.6
1.2
.8
.4
0.0
P=0.001
P<0.001
P<0.001
P<0.001
treatment groups
CsAhd RapPBS
tu
m
or
 w
ei
gh
t (g
)
3.0
2.5
2.0
1.5
1.0
.5
0.0
P=0.002
P=n.s.
treatment groups
CsAhd RapPBS
a
sc
ite
s 
vo
lu
m
e 
(m
l)
2.00
1.75
1.50
1.25
1.00
.75
.50
.25
0.00
P=0.001
P=n.s.
a
b
c
Figure 1 a Intraperitoneal administration of rapamycin, 5-FU, or
oxaliplatin resulted in tumor suppression. Box plots represent tumor
weights at the end of the experiment. Mouse colon carcinoma cells
(CT26; 5×105 cells) were injected into the peritoneal cavity of
syngenic Balb/c mice. Twenty-two days after intraperitoneal injection
of CT26 cells and 17 days after treatment initiation, mice were killed.
Treatment groups were: PBS; ld Rap low-dose rapamycin, 0.15 mg/kg
every 2 days; hd Rap high-dose rapamycin, 1.5 mg/kg every 2 days;
5-FU 100 mg/kg every 7 days for the first 2 weeks, then 50 mg/kg
every 7 days until the end of the experiment; and oxaliplatin
5 mg kg−1 day−1 for 5 days). The group size was n=8. Significant
tumor growth suppression compared to controls was noted in the
various treatment groups (t test). b Tumor growth was significantly
inhibited by orally administered rapamycin but not by the immuno-
suppressive agent cyclosporine A. Box-plots represent the weight of
peritoneal tumors. The tumor model is the same as in a. Treatment
groups were: PBS; hd Rap high dose rapamycin, 1.5 mg/kg every
2 days; cyclosporine A, 15 mg/kg every 2 days. The group size was
n=8. c Significantly smaller tumor size and less ascites formation were
noted in hd Rap compared to controls but not in the CsA group (t test).

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Figure 2 a, b Rapamycin combined with 5-FU or oxaliplatin
inhibited tumor growth more efficiently than rapamycin alone. Box-
plots represent weight of peritoneal tumors (a). Animals (n=8/group)
with established syngenic, orthotopic tumors (5 days after injection of
5×105 CT26 cells) were treated with rapamycin (hd Rap, 1.5 mg/kg
every 2 days) in combination with either 5-FU (100 mg/kg every
7 days for the first 2 weeks, then 50 mg/kg every 7 days) or
oxaliplatin (5 mg kg−1 day−1 for 5 days). All compounds were
administered i.p. Mice were killed 22 days after tumor inoculation.
Rapamycin combined with 5-FU or oxaliplatin inhibited tumor growth
more effectively than rapamycin treatment alone (t test). b Picture of
mice described in a: I PBS; II hd Rap; III 5-FU + hd Rap; IV Oxal +
hd Rap. Tumor load was significantly reduced by rapamycin alone and
in combination treatments of rapamycin with 5-FU or oxaliplatin. c
Treatment with rapamycin alone or in combination did not influence
body weight (n=8/group). Graphs depict body weight of mice from a
measured every second day after tumor cell inoculation. Mice were
treated with PBS, rapamycin, or a combination of rapamycin and 5-
FU or oxaliplatin as stated above (a). The body weight of control mice
(PBS), with tumor loads of up to 2.5 g and ascites formations, was
significantly different from that of the most effective treatment group,
with no macroscopic tumor and no ascites (hd Rap + 5-FU; P=0.04).
For the other groups, body weight tended to be lower than that of
control animals. No significant intergroup differences were noted
between treatments (one-way ANOVA). d Treatment with rapamycin
alone or in combination did not alter the ultrastructure of the liver.
H&E staining of liver samples (n=8/group) displayed no change in the
ultrastructure of the liver parenchyma after 17 days of treatment with
PBS, oxaliplatin, or a combination of rapamycin with oxaliplatin and
5-FU.
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more pronounced in mice treated with the combination of
rapamycin and 5-FU/Oxal compared to mice treated
without rapamycin, where no significant correlation to
tumor weight was observed. This suggested that both
TIMP-1 secretion from the tumoral tissue and the secretion
from healthy tissues were affected by direct TIMP-1
suppression and indirect suppression by mTOR inhibition
(the biological activity of rapamycin), respectively. Peritu-
moral tissue is likely to contribute to TIMP-1 serum levels.
However, the fact that human TIMP-1 serum levels
correlated well (correlation coefficient=0.75) with tumor
weight in mice carrying a human SW620 xenograft tumor
suggested that peritumoral TIMP-1 expression due to
inflammation or a reaction to increased tissue levels of
MMPs was not the dominant source of the TIMP-1
correlation.
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Discussion
Our results corroborate preclinical and early clinical
findings from various tumors that the mTOR-inhibitor
rapamycin has antitumor efficacy. Our motivation to
undertake this study was the observation that a 62-year-
old patient, immunosuppressed due to liver transplantation
for 2 years, was treated for adenocarcinoma of the colon
with peritoneal carcinomatosis by local resection and
adjuvant chemotherapy (FOLFOX). At that time, immuno-
suppression was changed to rapamycin. Two years later, he
experienced an incisional hernia that required repair. At that
time, peritoneal carcinomatosis had resolved but for one
small lesion. Now, 6 years after the initial diagnosis, the
patient is alive with no manifestations of peritoneal
carcinomatosis (personal observation).
In our syngenic and xenograft orthotopic mouse models
for peritoneal carcinomatosis, rapamycin treatment signifi-
cantly inhibited tumor growth. The pronounced antitumor
effect was consistently observed in our experiments. This
study extends other work that showed rapamycin activity
against colorectal liver metastases.6,8,34 We demonstrated
that this anticancer effect occurs even in more advanced,
late-stage disease and with either intraperitoneal application
or oral administration of rapamycin. This is relevant
because rapamycin (Rapamune ®) is a highly lipophilic
solution given orally to transplanted patients. In previous
studies on colorectal cancer, solvents (dimethylsulfoxide or
ethanol) that are cytotoxic were used for intraperitoneal
rapamycin injections.6 Here, we emulsified rapamycin in
distilled water and then applied this emulsion intraperito-
neally and orally, in order to minimize direct cytotoxic
effects. The route of application did not influence the
antitumor activity of rapamycin.
In order to mimic treatment regimens in potential future
clinical trials (e.g., FOLFOX plus rapamycin), we com-
bined rapamycin treatment with 5-FU and/or oxaliplatin.
The combination therapy showed improved efficacy for
colorectal carcinoma without increasing toxicity. In addi-
tion, when rapamycin was combined with half the
recommended dosing of 5-FU/Oxaliplatin, tumor suppres-
sion was equally effective. Thus, systemic toxicity and side
effects can be reduced with this chemotherapy in the
future.35 A recent study showed that a combination of
rapamycin with irinotecan had pronounced antitumor
effects on colorectal xenografts, dependent on the
hypoxic state of cells.34 In histologic evaluation of tumors,
we did not find necrotic patterns typical of oxygen
dependency.
Early studies in transplant rejection showed that rapa-
mycin down-regulated TIMP-1, a factor overexpressed in
patients with advanced colorectal cancer and associated
with advanced tumor stages, poor outcome, and chemo-
resistance.21,22,36 In this study, treatment with rapamycin
caused nearly complete disappearance of TIMP-1 in tumor
tissue samples. Because TIMP-1 has broad tumor-
promoting activity (pro-angiogenesis, anti-apoptosis; pro-
motion of cell growth and proliferation), one could
speculate that its down-regulation by rapamycin could be
another mechanism through which rapamycin mediates its
antitumor effects.37,38 We found that TIMP-1 expression in
the tissue and the serum correlated well with the antitumor
effect of rapamycin. A high rapamycin dose yielded lower
TIMP-1 than a low rapamycin dose for similar tumor sizes.
This suggested that TIMP-1 serum levels mirrored both
antitumor activity and biological activity. In addition, we
found that human TIMP-1 serum levels in mice carrying
human SW620 tumors correlated well with tumor weight
and that TIMP-1 levels were not influenced by treatment
with the immunosuppressive agent cyclosporine A. This
provided corroborating evidence that serum levels of
TIMP-1 reflected primarily tumor load and proliferation
rather than a reaction of the peritumoral tissue.39
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Figure 3 Growth of peritoneal xenograft tumors was significantly
suppressed by rapamycin alone or in combination with 5-FU
+oxaliplatin. Box-blots represent tumor weight in different treatment
groups. SW620 cells (5×105) were injected intraperitoneally in
athymic nude mice. Treatment was initiated after 7 days for a total
of 35 days, when mice were killed. Treatment groups (n=8) were:
Controls (PBS); low-dose rapamycin (ld Rap, 0.15 mg/kg every
2 days) per gavage; high-dose rapamycin (hd Rap, 1.5 mg/kg every
2 days) per gavage; 5-FU+oxaliplatin (5-FU, 100 mg kg−1 week−1, i.p.
for the first 2 weeks, thereafter 50 mg/kg every week + Oxal:
5 mg kg−1 day−1, i.p. for 5 days); and a combination of rapamycin
with 5-FU+Oxal (at above doses). Significant suppression of tumor
growth compared to controls was noted following oral administration
of rapamycin (ld Rap and hd Rap). Likewise, a combination treatment
of 5-FU + oxaliplatin significantly inhibited tumor growth. The
antitumor effect was synergistically enhanced by combination of
rapamycin with 5-FU+oxaliplatin compared to 5-FU+Oxal alone (P
values between groups: t test; intergroup differences: one-way
ANOVA).
J Gastrointest Surg (2009) 13:1781–1790 1787
TI
M
P-
1 
[pg
/ 1
 µg
 of
 to
tal
 pr
ote
in]
340
330
320
310
300
290
280
270
260
250
240
230
220
210
200
PBS
P=0.001 
Rap Rap
(50ng/ml)(5ng/ml)
a
B) PBS  A) H&E
C) 5FU+Oxal D) hdRap 
b
Tumor weight [g]
TI
M
P-
1 
[ng
/m
l]
0 
7500 
15000 
22500 
30000 
CC=0.771  
0.50.0 1.0 1.5
c
Figure 4 a Rapamycin down-
regulated TIMP-1 expression.
Forty-eight hours after cell-
cultures were treated with PBS,
5 ng/ml, or 50 ng/ml rapamycin,
the whole cell lysates of CT26
cells were analyzed for TIMP-1
expression by ELISA (normal-
ized to 1 μg of total protein).
Compared to PBS-treated cells,
a significant down-regulation of
TIMP-1 protein levels was ob-
served in the cells treated with
high-dose rapamycin (P<0.001;
t test). b Intratumoral TIMP-1
was strongly down-regulated af-
ter rapamycin treatment. Hema-
toxylin–eosin staining of
peritoneal CT26 syngenic tumor
from experiment in a (A). Sec-
tions were subjected to immu-
nohistochemistry for TIMP-1
(brown staining) and counter-
stained for nuclei (blue; B–D).
Cytoplasmic and extracellular
expression of TIMP-1 was
strongly reduced after rapamy-
cin treatment (D) compared to
controls (B). 5-FU+Oxal therapy
(C) led to a weak down-
regulation of TIMP-1 in the
tumors. c TIMP-1 serum levels
correlated with tumor weight.
Whole blood taken from the tail
vein of CT26 tumor-bearing
Balb/c mice at the time of
killing was spun down and the
serum analyzed for TIMP-1 ex-
pression by ELISA. Linear re-
gression analysis showed that
tumor weight was correlated
with TIMP-1 expression in mice
treated with PBS, FU/Oxal
alone, and in combination with
low- or high-dose rapamycin.
Data are representative of one
experimental run. A very good
positive correlation between tu-
mor weights and TIMP-1 serum
levels was calculated (correla-
tion coefficient=0.77 (Spearman
rank); P<0.005).
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Conclusion
The combination of rapamycin with 5-FU and oxaliplatin
had strong synergistic effects against late-stage colorectal
cancer even at reduced dosing. Hence, our findings suggest
that rapamycin combined with current state-of-the-art
chemotherapy should enter phase I/II clinical trials as a
treatment for late-stage colorectal carcinoma. TIMP-1
serum levels can easily be monitored as a surrogate marker
to measure antitumor activity in patients with peritoneal
carcinomatosis.
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